RAPT Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of RAPT Therapeutics generated cash of -$97,048,000, which is less than the previous year. Cash used in financing activities reached the amount of $1,447,000 last year. Net change in cash is therefore $8,532,000.
Cash Flow
| 2017 | -27.12M | -1.12M | 30.10M |
|---|---|---|---|
| 2018 | -32.95M | -3.5M | 52.73M |
| 2019 | -35.47M | -843K | 49.90M |
| 2020 | -40.49M | -87.43M | 75.46M |
| 2021 | -61.02M | -81.34M | 141.48M |
| 2022 | -70.77M | -45.49M | 131.18M |
| 2023 | -97.04M | 104.13M | 1.44M |
RAPT Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 38.94M | 24.02M | 24.91M | 77.38M | 63.79M | 47.51M | 45.66M |
Operating activities | |||||||
Net income | -116.79M | -83.83M | -69.20M | -52.89M | -42.99M | -36.14M | -29.11M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.21M | 1.04M | 996K | 1.12M | 1.33M | 1.23M | 1.38M |
Stock-based compensation expense | 17.09M | 11.26M | 9.95M | 8.68M | 2.05M | 0 | 716K |
| Deferred income tax benefit | 17.09M | 11.26M | 9.95M | 8.68M | 2.05M | 0 | 716K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 7.33M | 3.71M | 933K | 2.39M | 736K | 1.47M | -80K |
Cash generated by operating activities | -97.04M | -70.77M | -61.02M | -40.49M | -35.47M | -32.95M | -27.12M |
Investing activities | |||||||
Purchases Of Investments | -161.49M | -190.85M | -164.97M | -139.33M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.12M | -845K | -755K | -398K | -888K | -3.5M | -1.12M |
Acquisitions Net | 0 | 44.64M | 80.59M | 87.03M | 45K | 0 | 0 |
Cash generated by investing activities | 104.13M | -45.49M | -81.34M | -87.43M | -843K | -3.5M | -1.12M |
Financing activities | |||||||
Common Stock Issued | 1.44M | 129.78M | 139.46M | 75.46M | 35.52M | 266K | 246K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.44M | 131.18M | 141.48M | 75.46M | 49.90M | 52.73M | 30.10M |
Net Change In Cash | 8.53M | 14.91M | -891K | -52.46M | 13.58M | 16.28M | 1.85M |
Cash at end of period | 47.47M | 38.94M | 24.02M | 24.91M | 77.38M | 63.79M | 47.51M |
| Data source | Data source | Data source | Data source | Data source |